To investigate the effect of zoledronic acid (ZA) on fracture rate in children and young adults with both primary and secondary skeletal fragility.
Key Findings:
Overall median fracture rate decreased from 0.6 (IQR 0.3-1.1) to 0 (IQR 0-0.4) fractures per year (P < .001).
Significant reductions in fracture rates were observed in both primary (1.0 [IQR 0.6-1.5] to 0.3 [IQR 0-0.6]) and secondary (0.5 [IQR 0.1-0.8] to 0 [IQR 0-0.3]) skeletal fragility.
Fracture rate reductions persisted when limited to long bone or long bone plus spine fractures.
Interpretation:
ZA treatment is associated with significant declines in fracture rates among children and young adults with skeletal fragility, indicating its potential as an effective intervention.
Limitations:
Retrospective design limits causality inference.
Sample size may not represent all pediatric populations with skeletal fragility.
Lack of long-term follow-up data on fracture rates post-treatment.
Conclusion:
ZA is effective in reducing fracture rates in pediatric patients with skeletal fragility, supporting its use in clinical practice for fracture prevention.
